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SUMMARY
Our world is increasingly driven by data. Medical, economic and political decisions are made based on
automated analysis of ever-growing volumes of data, be they patient treatment decisions generated from rule
models or stock trading decisions made by micro-trading tools. Scientific discovery is now all but impossible
without data-intensive infrastructures, which have transformed both how science is done and what science
is done. The Learning Health System (LHS) community has taken up the challenge of bringing the complex
relationship between clinical research and practice into this brave new world.
At the heart of the LHS vision is the notion of routine capture, transformation and dissemination of data
and knowledge, with various use cases, such as clinical studies, quality improvement initiatives and decision
support, constructed on top of specific routes that the data is taking through the system. In order to stop
this increased data volume and analytical complexity from obfuscating the research process, it is essential to
establish trust in the system through implementing reproducibility and auditability throughout the workflow.
Data provenance technologies can automatically capture the trace of the research task and resulting data,
thereby facilitating reproducible research. While some computational domains, such as bioinformatics,
have embraced the technology through provenance-enabled execution middlewares, disciplines based on
distributed, heterogeneous software, such as medical research, are only starting on the road to adoption,
motivated by the institutional pressures to improve transparency and reproducibility.
Guided by the experiences of the TRANSFoRm project, we present the opportunities that data provenance
offers to the Learning Health System community. We illustrate how provenance can facilitate documenting
21 CFR part 11 compliance for FDA submissions and provide auditability for decisions made by the decision
support tools and discuss the transformational effect of routine provenance capture on data privacy, study
reporting and publishing medical research.
Copyright c© 0000 John Wiley & Sons, Ltd.
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KEY WORDS: data provenance, health informatics
1. INTRODUCTION
Our world is increasingly driven by data. Medical, economic and political decisions are made
based on automated analysis of ever-growing volumes of data, be they patient treatment decisions
generated from rule models or stock trading decisions made by micro-trading tools. Scientific
discovery is now all but impossible without data-intensive infrastructures [1], which have
transformed both how science is done and what science is done [2]. But, in this fresh landscape, there
needs to be an increased focus on the quality of data and research tasks, since new technological
advances and cultural paradigms may bring down the control zones that existed to ensure the quality
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of scientific data and the research process[3]. More generally, growth in size and complexity of data
and analytics surrounding it forms a black box around the reasoning behind important results and
decisions. Understanding the provenance of the data and processes that we are relying on has never
been more critical.
The Learning Health System [4] community has taken up the challenge of bringing the complex
relationship between clinical research and practice into this brave new world. At the heart of the LHS
vision is the notion of routine capture, transformation and dissemination of data and knowledge,
with various use cases, such as clinical studies, quality improvement initiatives and decision support,
constructed on top of specific routes that the data is taking through the LHS. These processes need
to be mirrored by routine availability of trust information at each step of the process, embedding
auditability and transparency in the very heart of the LHS.
This challenge is very timely, with the scientific community steadily becoming more aware of
the fundamental problems in the way research is reported and results submitted to scrutiny in the
post-publication stage [5]. Reasons for this are complex and interleaved, including positive bias,
intractable analyses and pressure on journals and authors to constantly deliver groundbreaking
research. Still, a consensus is arising that data-driven solutions are the way to ensure correctness
of science, making the LHS community, with its data focus, ideally positioned to spearhead this
drive for improvement in medical research.
This paper shall review the main reproducibility challenges that affect medical research, before
discussing the concept of data provenance as a way of embedding reproducibility into the LHS. The
experiences of the TRANSFoRm project will be presented as an exemplar on how to incorporate
provenance into three LHS use cases: epidemiological research, randomized controlled trials and
diagnostic decision support. Finally, the impact of such step change will be discussed and directions
for future research presented.
2. REPRODUCIBILITY CHALLENGES
While reproducibility has always been at the core of scientific method, it was only with the
digitalisation of the research task, that it has become possible for external scientists and teams to
attempt to fully reproduce research findings in-house, using identical software tools, and data, when
available. Two landmark studies that established the scale of the reproducibility crisis came from
pharmaceutical industry teams looking to validate details of published findings before dedicating
resources to productising them. A study by a team from Bayer showed that only 25% of 67 examined
academic papers could be replicated [6]. Meanwhile, scientists from Amgen looked at 53 preclinical
oncology studies published between 2001 and 2011, and found that only 6 (11%) could be robustly
replicated, with the unreproducible studies found to be attracting more citations than reproducible
ones [7].
The problem is by no means restricted to preclinical studies, even though their increased reliance
on computational instruments makes them easier to spot and test. The investigation in [8] looked
into twelve randomised clinical trials testing 52 observational claims and failed to reproduce a single
one. [9] described the replication of 100 experiments reported in papers published in 2008 in three
high-ranking psychology journals. Assessing whether the replication and the original experiment
yielded the same result according to several criteria, they found only about one-third to one-half of
the original findings were also observed in the replication study. Most recently, a random sample of
441 journal articles from biomedical journals from between 2000 and 2014 was studied and it was
found that none made all their data available, only one provided a full protocol, and the majority did
not disclose funding or conflicts of interest [10]. The cost of irreproducible research in life science
is estaimated at $28 billion per year in the U.S., with a quarter of that sum attributed to data analysis
and reporting [11].
Lack of reproducibility creates translational problems on two fronts. Findings in basic and
preclinical research that are supposed to set the agenda for the clinical studies and drug development
are often poor predictors for success in clinic [12, 13, 14]. At the other end of the research spectrum,
drugs with promising results in clinical trials are sometimes found to be underperforming in real
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world conditions - concept referred to as the efficacy-effectiveness gap[15]. While the lack of
transparency and insight into trial design and execution is by no means the only contributing factor
to this phenomenon, it is a significant contributor[16].
A number of institutions have emerged that are dedicated to promoting reproducible practices
in scientific research, such as the Center for Open Science (COS) in the US †, that provides free
and open services to increase inclusivity and transparency of research. Meta-Research Informatics
Centre at Stanford‡ (METRICS) is dedicated to building cross-disciplinary collaborations with
the view of improving research practices across biomedical disciplines. The UK’s Software
Sustainability Institute§ is focusing on the role of software in research reproducibility and promoting
best practices in documentation, version management, release procedures, licensing, and archiving.
2.1. Inadequacies of publishing culture
To adequately address the reproducibility failings some elements of the publishing culture need
revisiting to increase transparency and tractability. A joint statement by editors of Science and
Nature, following a workshop organised by National Institute of Health, highlighted the issue
[17, 18]. With regards to post-publishing guidelines, several common pitfalls in the process have
been noted, including reluctancy in publishing retractions, imposing fees for retracting articles or
publishing comments challenging the published articles, and not providing mechanisms for access to
raw data[5]. Proposals have been made that the research teams should curate their data and software
so that it is readliy available, and its scrutiny should form a required step of journal peer-review, e.g.
in COS’s Transparency and Openness Promotion (TOP) Guidelines[19] that have been endorsed by
538 journals at the time of writing.
To further these aims, the editors of the leading medical journals in International Committee
of Medical Journal Editors (ICMJE) made a proposal in the early 2016 to make public sharing
of data gathered in clinical studies as a condition of publishing the results in those journals. The
data concerned comprises deidentified individual-patient data underlying the results presented in the
article, tables, figures, and appendices or supplementary material, including necessary metadata[20].
This proposal has not been without its critics though, with access to data being a particular point
of contention. A recent editorial in NEJM [21] raised concerns about unsupervised use of data
by teams which lack understanding of the data and ethical and regulatory mechanisms around it,
and the emergence of a new class of ‘research parasites’ that focus on finding errors in published
research. The use of term created a significant backlash in the research community which prompted
a response by the journal [22].
2.2. Reproducibility in the LHS
Relying on the routine processes that both depend on research findings and produce further data for
research, Learning Health System is particularly vulnerable to failings in the quality of its research.
Being a systemic change across multiple settings, it requires demonstrable trust in its every segment.
We define four levels of reproducibility within the context of the LHS:
1. Auditability allows the research to be scrutinised according to some pre-defined
methodology. A certain subset of research information is made available for further
investigation.
2. Traceability establishes an unbroken chain of transformations that data underwent from its
capture to its contribution to research findings.
3. Replicability offers researchers the ability to repeat the experiments and findings with
identical tooling on original data.
†https://cos.io/
‡http://metrics.stanford.edu/
§http://www.software.ac.uk
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4. Reproducibility asserts that the scientific result can be independently confirmed on new data.
It would be wrong to assume that replicability is a neccessary precondition for reproducibility.
Indeed reproducibility requires that findings are robust enough to survive minute changes to
experiment design, whereas replicability avoids them by definition [23, 24]. However, it is the role
of traceability to establish exactly what happened during the experiment and provide reassurance
that sources of variability are indeed scientifically insignificant and that the abstracted principles
(e.g. p-values, confidence intervals) are sound. Thus, it is traceability that is central to establishing
transparency and trust in the LHS processes. It is worth noting that these issues do not apply
exclusively to research and that the same principles are applicable to routine quality improvement
initiatives, that form another important part of the LHS[25].
3. DATA PROVENANCE
A neccesary precondition for improving the reproducibility of medical research is to increase
the transparency of the research process, by including minute details that will allow subsequent
investigators to fully understand what was actually done. Reporting standards for cohort studies
[26, 27] or clinical trials [28, 29, 30] have long been the traditional means of providing this
level of rigour in medical research, but they are inadequate in a data-driven LHS, since they
can only provide auditability, often at significant resource cost, but cannot establish transparency,
much less traceability, replicability or reproducibility. Manually producing standardised reports
from a combination of notes and a collection of software artifacts, introduces space for mistakes
and omissions, accerbated by the natural tendency of researchers towards observational and
cognitive bias. [31]. Furthermore, such reports are typically not included with the original research
publication, and thus not readily available to readers.
Simply put, provenance describes what happened. W3C defines provenance as a form of
contextual metadata that describes entities and processes involved in producing and delivering
or otherwise influencing that resource. Provenance provides a critical foundation for assessing
authenticity, enabling trust, and allowing reproducibility[32] . The Office of the National
Coordinator (ONC) for Health IT describes it as Attributes about the origin of health information
at the time it is first created and tracks the uses and permutations of the health information over its
lifecycle.[33].
Data provenance technologies can provide traceability to the LHS by automatically capturing
the trace of the research task and resulting data in a uniform and domain-indepent way, thereby
facilitating reproducible research. The concept originated in the eScience and cyber-infrastructure
communities, as means of capturing the exact parameterisations and configurations of scientific
workflows that produced a particular data set [34, 35]. As the number of implementations grew,
the W3C developed the PROV interoperability standard [32] that models provenance data as graphs
where nodes represent data entities; activities produce and use those entities; and agents are actors
that control these activities, with graph edges denoting the relationships between the concepts [36]:
was-controlled-by, used, generated-by and others. While provenance data is not always stored in
graph databases, this model conceptually implies that the provenance questions of interest require
both traditional item-based querying and exploratory analysis, whereby the researcher can browse
the relationships between entities to find the answer [37]. An example of a provenance graph can
be seen in Figure 4, with entities denoted in blue, activities in red and agents in yellow. The graphs
are read in the direction of the arrows, thus in the figure the Query Result entity on the right was
generated by the Execute Query process that used the Data Collection Query entity, which has its
own further history recorded.
While provenance has a significant role to play in achieving reproducibility in the Learning Health
System, there are still gaps in its implementation methodology that stem from provenance having
emerged from computational fields with standardised software architectures. Provenance adoption
in non-computational disciplines, such as the LHS, presents several challenges:
Copyright c© 0000 John Wiley & Sons, Ltd. Lrn. Hlt. Sys. (0000)
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1. Problem domains, such as medicine, have established software ecosystems that can not be
easily replaced with provenance-enabled tooling without major investment and disruption;
2. Motivating such change can be difficult, particularly if the immediate benefit is unclear,
and without example provenance data for a particular problem domain, it is difficult to
demonstrate the capabilities of provenance analytics;
3. Existing provenance models provide a common syntax for representing provenance, but
creating semantically rich provenance models requires involvement of domain experts.
Furthermore, the specific goals of LHS being adaptable, self-improving, stable, certifiable, and
responsive [38] introduce additional desirable features in a provenance solution.
1. System transparency. The black box approach and lack of transparency results in the lack of
trust and is cited as one of the main reasons behind the poor take-up of medical software and
decision support systems in particular [39]. Therefore, in a provenance-enabled architecture,
activities related to usage and generation of data need to be readily available for users to
review.
2. Auditability of actions. The system must enable the user to look up an action performed in the
system and find all the relevant detail about how it was made - data sets used, exact versions of
software tools, human actors involved. The level of detail captured must be validated against
the required audit standard.
3. Understandability of data. The provenance metadata that is captured about the workings
of the system needs to be not only accessible to the users (clinicians, auditors, researchers,
patients) but it has to rely on standardized concepts expressed in terminologies the users are
familar with.
4. Validation readiness. In order to guarantee that the provenance metadata being captured
is at the right level of granularity and encompasses all the necessary features, the structure
of the provenance data needs to be modelled and verified separately from the software
implementation.
5. Privacy and security. Traditionally, security logs have been used to keep track of what is
going on in the system and investigate any inappropriate actions. The provenance model needs
to go beyond that and be able to demonstrate that a data set is never used contrary to its ethics
and privacy constraints.
6. Scalability. The system must be able to scale up in line with the expected usage volume, so
the provenance store needs to be appropriately specified to cope with accumulation of usage
data over time.
We shall now describe how the provenance infrastructure in one large-scale LHS project,
TRANSFoRm, addressed these issues.
4. IMPLEMENTATION OF PROVENANCE INFRASTRUCTURE IN TRANSFORM
.
The TRANSFoRm project ¶, was funded under EU Framework Programme 7 to develop a
common digital infrastructure for LHS applications, with the aim of integrating the data and
workflows of clinical and research domains in primary care. The project outputs include methods,
models, services, validated architectures and clinical demonstrations of software to support this
¶www.transformproject.eu
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Figure 1. Overview of TRANSFoRm software components
Figure 2. TRANSFoRm semantic stack. Study concepts are expressed in the Clinical Research Information
Model (CRIM), with data elements defined in the Clinical Data Integration Model (CDIM) and mapped onto
the local database structures defined in the Data Source Model (DSM), using local Data Node Connector
and Semantic Mediator components.
integration. The architecture that was developed is generic [40] and was applied across the project’s
three demonstrators: genotypic-phenotypic observational studies, randomised controlled trials, and
diagnostic decision support.
The TRANSFoRm software ecosystem, shown in Figure 1, comprises front-end tools that rely on
a set of generic middleware components, secure data transport, authentication, semantic mediation,
and data provenance, that provide essential shared functions for the LHS applications built in
TRANSFoRm.
One of the goals for TRANSForm was to provide maximum flexibility, presenting the lowest
possible barriers to entry for integrating EHR systems and datasets, reusing whenever possible the
existing data standards and methods for managing heterogeneity between data sources. The data
used in the LHS reside in multiple repositories, differing in structure and terminology, bringing the
need for a generic mechanism for mapping TRANSFoRm queries onto individual data sources. This
was delivered using a semantic mediation approach [41], combined with a standard data connectivity
Copyright c© 0000 John Wiley & Sons, Ltd. Lrn. Hlt. Sys. (0000)
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module, as shown in Figure 2 that illustrates the translation process for observational studies and
RCTs. Clinical concept data elements were modelled using the Clinical Data Integration Model
(CDIM) ontology [42], and local Data Source Models (DSMs) with the LexEVS tool used to support
binding of terminology terms to CDIM expressions. The research processes were modelled by the
Clinical Research Information Model (CRIM), which, in conjunction with CDIM, enabled a two-
level archetype to be defined for each required data element in the three use cases.
On top of these shared components, three application specific tools were built to support the
use cases: epidemiological study query workbench, clinical trial data collection and monitoring
tool and a diagnostic support plugin for EHR systems. The query workbench allows researchers
to design their queries from multiple data sources and translate their clinical terms into a list of
corresponding concepts from standard terminologies and classifications supported by the systems
they are working with. The queries are dispatched to the data sources via the middleware to the
local Data Node Connector that sits at the data source and translates the generic CDIM-based query
into a local representation using the Semantic Mediator component, and subsequently presents
that locally interpretable query (patient counts, flagging patients or data extraction) either to the
data source directly, or to a human agent for final approval, before returning the result. The RCT
module comprises computerised trial definitions using extended CDISC’s SDM/ODM standards,
with automatically generated electronic Case Report Forms (eCRFs) and Patient-Reported Outcome
Measures (PROMs). The former are filled in via a web browser by the clinician, while the latter are
completed by the patients using either web or mobile devices. The tool integrates with the EHR to
perform patient eligibility checks and enrolment, pre-population of eCRF data and to store a copy
of study data in the EHR. The TRANSFoRm Study System (TSS) coordinates study events and data
collections across multiple clinical sites. Finally, the diagnostic decision support tool is embedded
into the EHR and suggests to the clinician the diagnoses to consider, based on the patient record and
presentation cues entered. Recommendations are genereated by the central evidence service using
rules stored in the clinical evidence repository and annotated with levels of support and confidence
for the presenting case. The coded evidence cues and current working diagnosis can be saved back
to the patient EHR.
Data provenance capture in TRANSFoRm implements traceability across these three use cases,
which is necessary both to support trust and transparency and to enable learning and improvement
in LHS processes. The need to capture provenance data from a number of heterogeneous data
sources, without relying on each software tool to write its own provenance code, was addressed
by the concept of provenance templates. Introduced in [43] and [44], these are abstract constructs
which can be instantiated into concrete provenance graph fragments, that are added to the existing
provenance graphs. The fragments are defined in terms of meaningful operations within the LHS
problem domain, expressed using concepts taken from a relevant domain ontology (e.g. CRIM) and
that are mapped onto the provenance ontology PROV-O[45]. The choice of domain ontologies and
their mapping onto provenance concepts also determines the granularity of captured provenance.
Having established a set of meaningful actions that software tools in the domain perform, reflected
in the templates, a service interface was defined for those tools to invoke and capture provenance
without needing to undergo major redesign, as shown in Figure 3. While all the nodes and edges in
provenance graphs are annotated with ontological concepts, for clarity the images in the following
sections use human-readable labels derived from the concepts and identifiers.
The starting point for defining the provenance use cases was to express the use case requirements
as a series of provenance related questions. We list these generic provenance questions for each
use case to describe the provenance information that we require to be automatically recorded and
available about the LHS, and then show how it was implemented in TRANSFoRm.
4.1. Use case: Epidemiological studies
The provenance challenge in the observational domain is to ensure that the queries used to extract
data were aligned with the study protocol, and that any customisation required by the data sources
was correct and is available for auditing. Further useful feature is to track the popularity of individual
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Provenance database
Provenance server
TRANSFoRm software tools
(DSS, Cohort deﬁnition, CTMS...)
API calls
Neo4J graph 
warehouse
Querying and 
analytics
Extract-
Transform-
Load
Instantiated templates
Figure 3. Provenance architecture in TRANSFoRm. Software tools are agnostic to the underlying
provenance representation and invoke API calls that match some provenance template in the provenance
server. Template is then instantiated into a provenance graph fragment with appropriate ontological
annotations and persisted inside the relational database. The database is ETL-ed into a Neo4J graph data
warehouse which is used for querying and analysis.
WAS_CONTROLLED_BY
USED
WAS_GENERATED_BYUSEDWAS_GENERATED_BY TranslateCDIM…
Nivel
Query
Data Collection
QueryExecute QueryQuery Result
Figure 4. Provenance graph depicting an execution of a data extraction query in the epidemiological use
case. Blue nodes denote entities, red nodes are processes and yellow nodes are agents. The graph is read
from the bottom node which is a query result generated by the query execution process, which used a data
collection query that was generated by the translation process, controlled by the local data provider (Nivel)
and that was obtained from a generic query.
data sources and how they are being used. Thus, within the context of cohort studies from distributed
data sources, provenance information should allow us to find out:
• What was the exact query used in each database to select cases and controls for a study?
• How was a particular data extraction query modified before its final form, and what were the
performances of discarded versions?
• Which data items came from which data source?
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• Which are the most useful data sources across multiple studies?
This information is typically not readily available, particularly in a distributed query scenario,
with the researchers having to rely on local logs that need to be interpreted and combined to provide
full information, which adds to the resource cost of the study, potentially presenting a major problem
given the relatively tight financial constraints on observational studies compared to clinical trials.
The TRANSFoRm epidemiological use case was implemented using a front-end Query
Workbench that researchers used to define their queries and send them through the middleware
infrastructure to data sources. Three types of queries are supported (counts, flagging and
data extraction), each of which is expressed in a generic query model using generic CDIM
representations of medical concepts inside the queries, such as inclusion and exclusion criteria and
data fields to be retrieved. Once the query arrives at the data provider’s site, it gets translated into
the local representation, verified and authorised by the local data controller, and executed against
the database.
The provenance data that was captured in the use case, based on a set of templates, covered: users
logging in and being authenticated in the system, creation and editing of queries, and execution of
queries against the databases. All three of these scenarios were performed by different tools, first by
the authentication system, second by the Query Workbench, and the third by the Data Connector,
with the TRANSFoRm template-based provenance service collecting the data.
The provenance graph fragment shown in Figure 4 contains the trace of the third scenario,
visualised in the Neo4J database, with blue nodes as entities, red nodes as processes and yellow
nodes as agents. The Query Result entity at the bottom of the graph was produced by the Query
Execution process which used the Data Collection Query containing the actual SQL query which
was in turn obtained from the Translation process using a generic CDIM query and controlled by the
data controller at the data provider’s site (Nivel‖ in the example shown). The node labels have been
generated from the ontological categories and values that all nodes have been annotated with, taken
from TRANSFoRm’s CRIM information model. The freedom to annotate the nodes with categories
and values as per the requirements of the audit trace needed is a powerful mechanism for producing
traces targeted for particular types of reports.
4.2. Use case: Clinical trials
FDA’s final guidance on Electronic Source Data in Clinical Investigations [46] encourages use
of electronic source (eSource) data in the conduct of clinical trials intended for inclusion in
investigational and new drug applications, with the view that Electronic Data Capture from both
devices and trial participants has the potential to improve the reliability, quality, traceability,
provenance and integrity of data from electronic source to regulatory submission. However, this
effort is hampered by the lack of framework for capturing this metadata across various eSources.
In addition to providing an auditable research trail, the aim of using provenance in clinical
research is to achieve deeper understanding of the trial characteristics and how it impacted its
performance. So, some of the questions that can be addressed using RCT provenance data are:
• Which trials had the largest/smallest number of consent rejections?
• Which trials failed to recruit patients for whatever reason?
• Which eligibility criteria were too restrictive in terms of the numbers of recruited vs. expected
patients?
• Which EHR-s/locales were best at recruiting patients?
• What eCRF items in various sites were consistently not extracted from the EHR, but had to
be entered manually?
‖www.nivel.nl
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Figure 5. Fragment of a provenance graph depicting one patient’s data record being checked for eligibility,
patient being consented and randomised and having the first study form created. Blue nodes denote entities
and red nodes are processes.
• For a particular study participant, list all versions of a specified eCRF, together with the date
and the people involved in each modification.
• Retrieve details of informed consent for a patient who filled in a specific eCRF.
While some of these questions are answerable using the standard reporting functions of CTMS
tools, having a single audit repository becomes advantageous once several eSources and associated
software tools start participating in the trial process, e.g. CTMS, EHR, mobile data collection tools,
EHR adapters etc. and all their entries can be queried jointly.
In its Randomised Controlled Trials use case, TRANSFoRm implemented an EHR-driven clinical
trial system, in which the EHR system was used to significantly reduce the effort in running clinical
studies by automatically checking patients for study eligibility, using EHR data to part-fill Electronic
Case Report Forms (eCRFs), and coordinating the study workflow including mobile data collection
of Patient Reported Outcome Measures (PROMs). The resulting system was used to run studies
with over 600 patients in four European countries [47], and was validated for Good Clinical Practice
(GCP) [29]. Tractability of such system is of essence in order to understand, evaluate and potentially
improve the trial design. This requires the minute study details, e.g. eligibility criteria encodings,
how they were applied to individual patients who presented to the clinician, data extracted from the
EHR systems, data collected through eCRFs and the analysis performed on the collected data.
Similarly to other use cases, assembling the trace of the entire process used provenance data
captured from multiple tools: the TRANSFoRm Study System, EHR system and the eCRF/PROM
data collection tools. The provenance traces for RCT were significantly more complicated than
the other two use cases, however, since they had to cover patient eligibility checks, consenting,
randomisations, and data collections through eCRFs and PROMs, together with the interactions
between eCRFs and the host EHR.
A fragment of the collected RCT provenance data is shown in Figure 5. As in the previous
example, red nodes denote activities and blue are entities. The graph shows one patient’s data
record being checked for eligibility, patient being consented and randomised and having the first
study form created. The implementation uses the provenance ontology for Randomized Controlled
Trials (RCTPO) to provide trial-relevant semantic annotation on the provenance nodes [43], and
nodes are labelled with concepts from RCTPO. The values of the nodes contain various information
relevant to the concept, e.g. eCRF document definition in ODM, EHR version, timestamp etc. It is
important to note that no patient identifiable information was stored in the provenance logs as these
were kept separately from the research database, so the eCRF provenance entity contains the eCRF
identifier in the TRANSFoRm Study System, but not the actual data stored inside.
4.3. Use case: Decision support
The notion of trust is central to the LHS vision of routine capture, transformation and dissemination
of data and resulting knowledge and an essential aspect of that trust is to ensure transparency at
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each step of the process. When applied to decision support systems, this translates to the ability
to readily demonstrate the clinical reasoning that was performed in a clinical encounter, together
with the recommendation received and a full trace from that recommendation back to the rules
applied to produce it. Similarly to the RCT case above, although EHRs typically have auditability
features, third-party plug-ins and DSS-s often do not, questioning their ability to meet medical
device certification standards.
The key provenance questions that are relevant to decision support systems are:
• Which clinician used the decision support tool to make a specific diagnostic recommendation
for a specific patient at a specific point in time?
• What clinical evidence cues supporting diagnosis of a particular diagnostic condition were
matched to a particular patient evidence set as part of an evidence comparison process that
was run at a particular point in time?
• Which rules are most frequently fired for a particular set of symptoms?
• Which rules are never getting used?
• In which decisions was a particular rule/guideline applied?
Generic decision support systems use a standardized model representation to encode the rules
and guidelines that they implement. Should one such rule be found to be invalid or potentially
harmful, it is important to be table to trace all usages of that rule, this is sometimes referred to as
taint analysis. As an added benefit, accumulated provenance traces describing rule usage form a
potentially valuable resource when assessing rule performance in practice.
In its third use case, TRANSFoRm has developed a prototype next generation diagnostic decision
support system. The tool is driven by clinical knowledge obtained through a web service based
clinical evidence repository and is embedded into a family practice EHR system (InPractice Systems
Vision 3 EHR). The user enters observed patient cues with potential differential diagnoses being
dynamically ranked, the cues are sent to the recommendation engine and suggested diagnoses are
returned. Upon exiting the tool a working diagnosis can be confirmed and the coded evidence cues
and current working diagnosis can be saved back and recorded for future reference in the patient
EHR.
Two DSS scenarios were identified as being relevant to capture through provenance metadata. The
first use case describes the necessary provenance collection requirements for evidence production,
generation and update of evidence either through manual evidence update or through evidence
generated automatically from the use of data mining tools. The second use case supports provenance
collection during evidence consumption and subsequent clinical recommendation provided by the
deployed evidence repository accessed by the decision support tool itself.
An example provenance trace from the second DSS scenario is shown in Figure 6, with blue nodes
representing entities, red nodes activities and yellow nodes agents, as described previously. This
provenance trace shows the history of the DSS Recommendation entity on the far right, detailing
how it was produced by a Clinical evidence comparison process which compared cues obtained from
the patient with the evidence residing in the Clinical evidence repository (yellow actor node), with
the full details of the cue collection and the DSS and EHR systems captured as well. The ontological
concepts annotated onto the nodes and used to derive labels, are taken from the TRANSFoRm’s
Clinical Evidence Model (CEM) ontology, containing relevant DSS concepts, and aligned with the
constructs in the PROV model, in the same manner as in the other use cases.
5. DISCUSSION
In order to implement traceability, TRANSFoRm developed a generic solution for capturing
provenance data in Learning Health System applications, based on provenance templates and use of
domain ontologies to attach precisely defined meaning to the collected metadata, and thus addressed
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Figure 6. DSS provenance graph depicting the origin of a recommendation made by the system (top right).
Its origins are traced back via the evidence comparison performed by the rule base and the patient cues
presented all the way to individual EHR (InPS Vision) and DSS software instances used.
the three provenance challenges identified earlier. The use of a REST-ful service API that hid the
provenance-specific detail behind high-level service calls minimised the effort needed to connect
software components to the provenance system. Using example provenance graphs, based on the
abstract template constructs, enabled creation of prototype reports and analytics to discuss with the
end users. Such early prototypes can serve as powerful incentives for provenance adoption. Finally,
the use of concepts taken from the relevant domain ontology when defining tempates, ensured that
the structure and level of granularity of provenance metadata has been understood and agreed by
the domain users. With regards to the further features mentioned in Section 3, our solution offers
full transparency and auditability of data entities and their histories, allowing for demonstrable
adherence to security policies, while the understandability of captured data is provided through
use of domain ontologies, which in combination with the templates facilitate the validation task.
The provenance work in TRANSFoRm was a pioneering effort in the field and the next step is
to conduct a detailed evaluation in each of the three problem domains by formally validating the
template instruments and collected data against relevant standards and investigating the scalability
aspects, with projects already under way in the decision support and clinical trials domains.
Provenance solutions can of course be implemented locally, so that they are specific to problem
in hand. However, a generic approach, such as the one employed in TRANSFoRm, enables us
to reuse the same infrastructure for multiple applications so that, for example, a system used
for clinical trials, could also support the observational studies performed in the same institution.
Apart from financial benefits, this approach supports a greater degree of connectedness between
studies, facilitates long-term data reuse within an environment and increases the quality of metadata
available about the institutional datasets, all of which become further incentives for provenance
adoption.
Closely related to the issue of trust that has been discussed is the concept of security of provenance
data. Ideally, we would want the provenance traces to act as a central piece of metadata about the
LHS task observed, amenable to reporting the task to a variety of stakeholders, providing both
detailed and high-leveled views depending on the audience. For tasks involving sensitive data or
steps, mechanisms have been developed to abstract portions of provenance graphs that should not be
made accessible to certain users[48, 49]. Thus, if we were looking into provenance of a clinical trial
process, the researcher may be able to see the full detail of the patient recruitment and eligibility
checks performed on each patient, while the provenance version published with the paper would
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only contain the study eligibility criteria used and recruitment outcome, without revealing individual
patient’s profiles.
5.1. Related work
The full provenance architecture and the details of the template model used in TRANSFoRm are
currently submitted for publication and under review. The templates that the solution is based on
are similar to the efforts of the team at University of Southampton [50], with the main difference
being that their work is better suited to atomic instantiations, where each template is immediately
instantiated in full, while the TRANSFoRm model allows for variable repetitions (e.g. sequence of
edits to a study protocol). The PRIME methodology [51] covers the lifecycle of provenance model
design, from use case specification to identification of actors, processes, and information flows,
but it stops short of defining the architecture for provenance capture, the joint work on which is
underway. Related to our use of ontologies for constraining provenance artifacts, is the wider effort
in the use of ontologies as part of the software engineering process [52], e.g. through translations
between ontologies and UML constructs [53]. A broader overview of provenance implementation
issues in biomedical research can be found in [44].
Recently, the DPROV initiative ∗∗ has been working on aligning data provenance with the
HL7 and FHIR protocols, with the goal of identifying opportunities within CDA R2 where basic
provenance information about clinical (and other care related information) can be integrated, e.g.
who created it, when was it created, where was it created, how it was created, why it was created
and what action was taken to produce the information captured, thus enabling detailed audit of the
data entry process.
Deciding the level of granularity of provenance capture is a recognized problem in the field.
Indeed, there are infrastructures that collect finely grained provenance, on the level of the operating
system (Hi-Fi[54], SPADE[55], PASS[56], and PLUS[57]) or of individual programmatic scripts
(noWorkflow[58]). In both cases, the scale of captured data and lack of semantics make the resulting
provenance trails difficult to link to underlying research domain. Our approach minimises the
disruption required to instrument existing code by interleaving provenance-specific elements into
the code, in line with the principles of aspect-oriented programming [59]. An alternative approach
is to reconstruct provenance from separately maintained logs [60], but this comes at the cost to the
level of confidence in the resulting provenance data.
As part of the W3C PROV initiative, a comprehensive survey of available provenance
implementations was assembled in 2013, which lists a wide range of provenance-related software
tools at various levels of maturity [61].
5.2. Use of provenance for validation against standards
An important goal for the LHS community is to use provenance to demonstrate compliance of the
software tasks executed with applicable standards and regulations. The most obvious example in the
clinical trial domain is Title 21 of the Code of Federal Regulations; Electronic Records; Electronic
Signatures (21 CFR Part 11) [28] and Good Clinical Practice (GCP) [29] standards in the US and
EudraLex Vol. 4 Annex 11: Computerised Systems in EU [62]. Provenance can act as enabling
technology to help software tools address the Technical Controls of 21CFR-Part11 that regulate
electronic records, namely:
(a) Discerning invalid or altered records
(b) Generating accurate and complete records
(c) Controlling task sequencing when event order is important (i.e., operational checks)
(d) Protecting records throughout the record retention period
∗∗http://wiki.siframework.org/Data+Provenance+Initiative
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(e) Generating an audit trail through the record retention period contains date/time of operator
entries, description of actions taken, and is cumulative
(f) Limiting access to the system to authorized individuals
(g) Limiting access to system functions to authorized users (i.e., authority checks)
(h) Limiting data input to authorized sources (i.e., device checks)
(i) Protecting transmission of data from point of creation to receipt
Addressing these in turn, (a) can be achieved by tracking access to each record and the user/actor
who performed it. Analysis of captured provenance data can ensure that (b) is satisfied, although
that can be checked on the main record repository as well. The sequence of steps executed, required
in (c) can be proven using timestamped provenance traces and causality relationship between the
nodes. (d) is needs to be addressed at the data management level, where mechanisms such as non-
repudiation can be implemented, but provenance security techniques can be deployed to implement
secure views on a single provenance metadata repository. (e) is ideally suited to being answerable
using provenance audit trail since data provenance techniques allow all required information from
multiple software and human actors to be placed in a single audit database using a uniform data
model. (f) and (g) can be asserted by checking for the human agents that executed relevant processes
in the provenance trace. Similarly, for (h) such checks can be applied to software agents. Finally,
for (i) provenance provides an unbroken chain of actions and transformations that apply to the piece
of data.
By extracting relevant parts of the provenance trace, reporting can be automated in accordance
with the relevant standard, such as consolidated standards of reporting trials (CONSORT) [30].
Similar standards exist for reporting of cohort studies, such as Strengthening the reporting of
observational studies in epidemiology (STROBE) [26] and REporting of studies Conducted using
Observational Routinely-collected Data (RECORD) [27], and same principles can be applied to
them as well, as long as suitable ontological annotations are provided on the provenance traces.
A significant advantage of data provenance technologies over standard logs for validation
purposes is its ability to provide uniform history record across multiple software tools, thus
creating a single audit trail to be examined, with consistent timestamping and simplified security
and hosting policies. When used for reporting and audit purposes, it is important to validate
the provenance captured against the structure, content and granularity required by the applicable
standards. Mechanisms for specifying the structure of provenance traces, like provenance templates
used in TRANSFoRm, allow conformance to standards to be established at design time, facilitating
validation. In such scenarios, it is also useful to treat provenance data stores as an adjunct part of
the study database to ensure that relevant study information can be either replicated or referenced
from the provenance entries.
6. CONCLUSION
Looking back at the four levels of reproducibility in the LHS introduced earlier, we have established
that data provenance provides us with the traceability of data and processes. If those provenance
traces contain sufficient detail and are using the correct domain conceptualisation (i.e. through
well selected ontologies), they can be used to guarantee auditability as well. Replicability is
more easily achieved in computational use cases with few non-deterministic elements, such as
a diagnostic recommendation, or a data extraction and subsequent statistical analysis. In such
scenarios, provenance, together with original data and software used, guarantees replicability.
Finally, reproducibility is facilitated by the presence of full provenance information, ensuring
detailed understanding of what occurred in the observed task, but also the methodological soundness
of the techniques applied.
Ultimately, LHS aims to scale up health systems, and consequently the associated research that
health systems are built upon. If this scaling up is to succeed we have to embed mechanisms to
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verify trust in the system inside our research instruments. In the research world increasingly reliant
on electronic tools, provenance gives us a lingua franca to achieve traceability, which we have shown
to be essential to building these mechanisms. In order to realise the vision of making computable
provenance a feasible approach to implementing reproducibility in the LHS, we have to provide
viable mechanisms for adoption. These include defining meaningful provenance models for problem
domains but also introducing provenance support to existing tools in a minimally invasive manner.
The applicability of data provenance to the challenges facing the LHS was demonstrated in a
provenance infrastructure that was implemented in the TRANSFoRm project in three distinct LHS
domains, those of observational studies, clinical trials, and decision support systems. The challenge
now is to address the provenance gap that exists between the provenance metadata collected and the
reporting requirements of different domains, and perform a full evaluation in each domain, which
will require a joint effort by a range of stakeholders, including medical scientists, informaticians,
publishers and regulators. However complex and challenging, this work is essential if the quality of
translation from research into practice in the LHS is to improve with the growing volume of data
and research, rather than deteriorate and get lost in the noise.
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